[Locoregional recurrence of ovarian cancer: the place of surgery].
Standard therapy for advanced ovarian cancer includes cytoreductive surgery associated with platin based chemotherapy. Secondary surgery for recurrent ovarian cancer remains controversial. Actually there is not randomized trial based on this question. Furthermore literature shows that patients with recurrent disease may derive a significant survival benefit from optimal debulking. The datas availables indicate that prolonged disease free interval and feasibility of complete surgical resection are the main prognosis criteria. Proper selection of patients with recurrent ovarian cancer is essential to improve the therapeutic benefit of secondary surgery. There is a large place for trials and evaluation of innovatives techniques as hyperthermic intraperitoneal chemotherapy or intraperitoneal radio-immunotherapy.
Classe
Jean-Marc
JM
Service de chirurgie oncologique, Centre René-Gauducheau, 44805 Nantes-Saint-Herblain. jm-classe@nantes.fnclcc.fr
Catala
Laurent
L
Marchal
Frédéric
F
Ferron
Gwenael
G
Dravet
François
F
Pioud
Raphaelle
R
Descamps
Philippe
P
D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D011183:Postoperative Complications